Bristol Myers, Exelixis announce four-year results from Opdivo-Cabometyx trial

Bristol Myers (BMY) and Exelixis (EXEL) announced four-year follow-up results from the CheckMate -9ER trial evaluating Opdivo in combination with CABOMETYX vs. sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma. Results continued to show superior progression-free survival and objective response rates in patients treated with Opdivo plus CABOMETYX over sunitinib, regardless of risk classification based on International Metastatic Renal Cell Carcinoma Database Consortium scores. Superior overall survival was also observed in patients treated with the combination. These updated results, including data showing health-related quality-of-life benefits with Opdivo in combination with CABOMETYX vs. sunitinib, will be featured in an oral presentation at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium from January 25-27, 2024. “Renal cell carcinoma can be very challenging to treat and patients who are diagnosed with advanced disease or develop metastasis often face poor outcomes,” said Maria Teresa Bourlon, Urologic Oncology Clinic, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico. “These updated results from the CheckMate -9ER trial continue to support the role of nivolumab in combination with cabozantinib as an important first-line treatment option for this devastating disease, demonstrating durable efficacy across its multiple study endpoints, including a 23% reduction in the risk of death.” At a median follow-up of 55.6 months, all patients randomized to the Opdivo plus CABOMETYX treatment arm continued to experience benefits over those who received sunitinib across efficacy endpoints.